share_log

海利生物(603718.SH)：药明海德主要进行的是疫苗的CDMO业务

Hailey Biotech (603718.SH): Pharmaceutical Minghyde is mainly engaged in the vaccine CDMO business

Gelonghui Finance ·  May 5, 2023 16:00

Gelonghui May 5th 丨Some investors asked Hailey Biotech (603718.SH) on the investor interactive platform, “How is the anti-cancer vaccine developed by the subsidiary Pharmaceutical Mingheide progressing, and is it undergoing clinical trials?”

Hailey Biotech replied that Pharmaceutical Hyde is mainly engaged in the vaccine CDMO business. For the relevant situation, you can pay attention to the relevant regular reports disclosed by Pharmaceutical Biotech and the company.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment